MARKET

INAB

INAB

IN8BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.16
-0.59
-8.74%
Closed 16:00 11/29 EST
OPEN
6.80
PREV CLOSE
6.75
HIGH
6.82
LOW
6.06
VOLUME
27.25K
TURNOVER
--
52 WEEK HIGH
10.32
52 WEEK LOW
5.76
MARKET CAP
115.53M
P/E (TTM)
-9.4247
1D
5D
1M
3M
1Y
5Y
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...
Globe Newswire · 11/11 12:00
BRIEF-In8bio Posts Q3 Loss Per Share Of $0.25
reuters.com · 11/10 23:08
IN8bio, Inc. - Common Stock Q3 EPS $(0.25) Up From $(0.60) YoY
IN8bio, Inc. - Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.25) per share. This is a 58.33 percent increase over losses of $(0.60) per share from the same period last year.
Benzinga · 11/10 22:29
IN8bio reports Q3 results
IN8bio (NASDAQ:INAB): Q3 GAAP EPS of -$0.25. Press Release.
Seekingalpha · 11/10 22:13
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentat...
GlobeNewswire · 11/04 12:00
Possible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree
Insiders who bought US$1.0m worth of IN8bio, Inc. ( NASDAQ:INAB ) stock in the last year recovered part of their losses...
Simply Wall St. · 11/01 13:28
BRIEF-In8bio’S Announces Publication Of Preclinical Results In Mouse Models Of Glioblastoma Multiforme
reuters.com · 10/27 12:44
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.
Benzinga · 09/14 11:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INAB. Analyze the recent business situations of IN8BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average INAB stock price target is 15.50 with a high estimate of 19.00 and a low estimate of 12.00.
High19.00
Average15.50
Low12.00
Current 6.16
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Q2 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 13
Institutional Holdings: 1.77M
% Owned: 9.45%
Shares Outstanding: 18.75M
TypeInstitutionsShares
Increased
0
0
New
13
1.77M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.73%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Chairman/Director
Alan Roemer
President/Chief Executive Officer/Director/Primary Contact
William Ho
Co-Founder/Executive Vice President/Chief Scientific Officer
Lawrence Lamb
Chief Financial Officer
Patrick Mccall
Vice President - Operations
Melissa Beelen
Vice President - Operations
Kate Rochlin
Other
Trishna Goswami
Director
Peter Brandt
Director
Thomas Cirrito
Director
Travis Whitfill
No Data
About INAB
IN8bio, Inc. is a clinical-stage biotechnology company. The Company is focused on and developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The Company's product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).

Webull offers kinds of IN8BIO, Inc. stock information, including NASDAQ:INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.